This company has no active jobs
The END Fund
ORGANIZATIONAL OVERVIEW
The END Fund is the world’s leading collaborative philanthropic investment vehicle dedicated to controlling and eliminating neglected tropical diseases (NTDs). NTDs are parasitic and bacterial infectious diseases – including intestinal worms, river blindness, trachoma, schistosomiasis and lymphatic filariasis – that affect over 1.7 billion people globally. The END Fund’s vision is to ensure people can live healthy and prosperous lives free of the risk of NTDs and has set out to accomplish this by:
- Mobilizing and investing resources for maximum impact,
- Advocating for innovative, integrated and cost-effective NTD programs; and
- Facilitating philanthropic and private sector engagement to end these diseases.
By engaging a community of activist-philanthropists and taking a systems approach, the END Fund works in collaboration with governments, local and international NGOs, pharmaceutical companies, and academic partners on the global campaign to control and eliminate the most prevalent NTDs by 2030.
Since our founding in 2012 through 2019, with our partners, the END Fund has provided over 920 million treatments for NTDs worth more than $1 billion. In 2019 alone, we reached more than 121 million people with more than 196 million NTD treatments, representing an almost 10-fold increase from 2012. The END Fund works globally in over 25 countries, with a primary emphasis in Africa. You can read more about the END Fund and our 2019 impact story here.
